Dr. Terry Barnhart uses the example of Operation Warp Speed and COVID-19vaccines to show how we can speed up pharmaceutical innovation. Learn more today!
A director of product management shares what works and what doesn't when implementing Agile within drug discovery organizations. Learn more today.
Scientist and Agilist Kendra West shares tips for introducing Agile practices within scientific project management. Learn from her findings today.
Dr. Terry Barnhart shares how your company can boost innovation through Agile pharmaceuticals. Start accelerating your innovation today.
EG Life Sciences is sharing the news of Eliassen Group’s updated brand. Read more about what this means for us – and our clients.
Most IVD manufacturers are taking the necessary steps to prepare to comply with the IVDR. Are you ready to meet the IVDR requirements for Certification?
Do you know how to handle drug product that is considered “out of specification,” or OOS? Use this OOS guidance in case it ever happens to you.
Net Promoter Scores are derived with one basic question in mind: How likely are you to recommend your firm to a friend or colleague? This blog post explains what an NPS is, how it’s measured, and what this number actually tells you.
After the FDA inspects a company’s manufacturing facilities, they might send an FDA Form 483 or an FDA warning letter. Find out what to expect from both.
Is your Site Inspection Readiness team prepared for FDA visits, especially when they are unannounced? Make sure you have this FDA audit checklist on hand.
For life sciences companies, FDA inspection readiness is a necessity. Some FDA site inspections are surprise visits, so it’s wise to have a plan in place.
PhUSE is hosting the event, “Utilizing Risk-Based Monitoring to Identify and Mitigate Risk While Ensuring Patient Safety, Data Quality and Integrity”